Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. - Wikidata - awgldk - TriplyDB

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

http://www.wikidata.org/entity/Q36395100

about

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?Bladder Cancer Implications of LINE1 methylation for bladder cancer risk in women.Spotlight on differentially expressed genes in urinary bladder cancer.DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer.Long-term exposure to cigarette smoke extract induces hypomethylation at the RUNX3 and IGF2-H19 loci in immortalized human urothelial cells.Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.Association of secondhand smoke exposures with DNA methylation in bladder carcinomas.Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing.Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients.Bone marrow mesenchymal stem cells differentiate into urothelial cells and the implications for reconstructing urinary bladder mucosa.Cigarette smoking and subtypes of bladder cancer Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas Revealing signaling pathway deregulation by using gene expression signatures and regulatory motif analysis.Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression.Epigenetic alterations in bladder cancer and their potential clinical implications.Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study.Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation-dependent probe amplification.A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays.Chemotherapy practices and perspectives in invasive bladder cancer.RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.Developmental origins of epigenetic transgenerational inheritance Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.Molecular alterations associated with bladder cancer initiation and progression.Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis.Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer.Molecular determinants of tumor recurrence in the urinary bladder.ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion Hypermethylation in bladder cancer: biological pathways and translational applications.Noninvasive approaches for detecting and monitoring bladder cancer.The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22.p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation.

P2860

Q24604540-3EB71F23-8D0D-4337-881C-EFF46BF9026A Q26795518-9CF41939-959E-438F-B268-921B2A7CD67C Q30230812-6EEEB583-41ED-480A-B721-3509D0263FA9 Q33699273-A7876AA7-E5B8-421E-8A97-55B992FDE988 Q33869194-D0DFA80A-0845-459D-B100-4AB3AEDABAE2 Q34253377-5258FC00-8D6B-4F87-8DEF-876166A82FFB Q34750111-7AAEF27C-0A32-4FD3-B6A4-BDB275124E28 Q34760755-B584EF87-EDC6-42D0-B1AA-20F05FF73609 Q35118861-94FBDA0D-6B8A-447A-9DBE-8CCEC15E40FF Q35119047-F031A400-05F7-43D4-9C2F-F2E0D1988B09 Q35125879-25B50FAD-2ECA-4C67-A92B-1807F7C0BC4A Q35167858-2F0384D4-0F7F-4D9C-9E50-801DC3D840D6 Q35223703-F1FC2750-C1C3-46A5-958B-BBE91747EFC1 Q35535796-98798426-12DF-4ADF-B421-4DD3239F6DA7 Q35589281-ED8D3609-7A85-4E8D-BA3C-7F2EA8D0D8F4 Q35612218-47D16562-D993-48A5-9625-B2034A8824F7 Q35906452-FB675403-5706-4AE5-AA62-A14B84C9C32F Q36061127-59FB541D-6BCA-4C77-992A-7CC52E184DBE Q36095652-8F33D58F-D2B3-4A56-BFEC-3B321D6E74E6 Q36095721-76D9E388-7B85-4257-A6A8-A6FBC6198BF7 Q36158277-2002FAD0-8FE6-420B-AF1E-0D068B68367D Q36528408-A6E7E78C-C2C9-4F4A-B63D-FF26078D0A5E Q36561739-63854630-D9D5-401E-80B2-7081FAD99D32 Q36614005-DF4EFC48-9AD8-4B4B-B262-76B65EACC2EB Q36614678-88CDF3B7-D478-4B10-99AD-254B3EDC752A Q36636656-1DE161E2-34AD-4947-BF92-950D964D431E Q36877220-B6EEF3A2-4515-4272-B87B-62BF61A323A5 Q36882005-48A79A68-5F30-46FC-B099-3942F4DEF38F Q37065384-975C07FF-54E1-4FCC-A7EA-8EA7D98A3DF2 Q37122307-3A8E3E1F-BC88-4E57-AD22-1BEA4E505E74 Q37279001-FA727172-85EB-4717-AB9C-9CB02C7AD232 Q37480033-193EA046-77D1-466B-A760-6F8C88BF7FAA Q37481912-8465FA1E-047F-46EF-94CA-ACA076BEFFD5 Q37508037-B1B566DA-1F95-4809-9E72-0424DF0A9191 Q37575626-CAA5A588-ED01-470F-B5EA-6A7975CB3307 Q37619797-C765F0F7-D497-4788-AE5C-D4535B6FD436 Q37978544-F671F8CF-4367-4B41-9119-8867847D7DC9 Q38286089-CFC8AF3D-7A34-4E63-9054-4B5736BC2418 Q38618562-D20519EA-F89E-43C9-9549-DBA2C2105C91 Q38806678-74A7E027-01A6-4556-BB93-BFBDCC2EA6E4

P2860

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

http://www.wikidata.org/entity/Q36395100

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@ast

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@en

type

label

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@ast

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@en

prefLabel

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@ast

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@en

P1433

Q36395100-3074B7D6-AF09-4DFA-921A-47A69148FD9B

P1476

Q36395100-89B528B4-1B5B-48EC-8497-158D855B3BF2

P2093

Q36395100-49A46CA3-FD4A-46B7-A48E-D540E6026F52

Q36395100-C440D827-B5E9-4309-B09B-0F8C4E5618D7

Q36395100-D843BB2E-9312-40A8-85BA-3220C7142451

P2860

Q36395100-096D1CC8-1C19-4D75-B81D-47C316FF70F4

Q36395100-0E2C82B7-D097-4FDB-AE60-DD917FBC2D91

Q36395100-1DA9B9E4-AE57-4C8A-9E84-DD545E1029D6

Q36395100-47006134-1730-4A15-AAD9-240C82C4701D

Q36395100-488F082E-C899-4261-A84F-0A4FD33B4CBA

Q36395100-5A30B61F-CE72-451A-A7CC-770FCBC6CE9F

Q36395100-5A77E0A6-BB34-4642-B456-B1F18970CD51

Q36395100-5D0485AC-1E63-477E-81E2-F28E5B2A6155

Q36395100-6BFA654A-53DF-400F-8EEA-6FF550F747AD

Q36395100-763DC95D-5288-4DE7-A3A1-F2D2F2A3DE76

P2888

Q36395100-80A7A28B-15C3-4358-A931-B0C834B2BEB7

P304

Q36395100-CACBDB10-15BA-4900-8F93-AFD0A3687DD6

P31

Q36395100-4D34D456-94F2-4783-A9EB-B74602D59781

P356

Q36395100-B22271E4-1315-4DC8-A364-AB78B9C42C88

P407

Q36395100-3705C9A5-977B-4246-BE42-77DC34ADC8BB

P433

Q36395100-0E2CDBDF-9587-423D-878F-83BB0DE0CE8F

P478

Q36395100-F18D86DA-3681-4F3F-9391-3247F9CACF35

P577

Q36395100-F742E8B0-EB13-4FF2-AB3A-F6BC8BA00EB8

P6179

Q36395100-8820800C-9277-47E1-8676-B5ECFFDAE129

P698

Q36395100-D34ACE21-22DE-48E2-82A8-1EFD0C1FDAC0

P356

P1433

Nature Reviews Urology

P1476

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

@en

P2093

Erika M Wolff

http://www.w3.org/2001/XMLSchema#string

Gangning Liang

http://www.w3.org/2001/XMLSchema#string

Peter A Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1

DBCCR1 mediates death in cultured bladder tumor cells

Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK

RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2.

DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters

Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

The role of Ras superfamily proteins in bladder cancer progression.

The E2F transcriptional network: old acquaintances with new faces.

The genetics of transitional cell carcinoma: progress and potential clinical application.

P2888

P304

502-510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCPURO0318

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045623818

http://www.w3.org/2001/XMLSchema#string

P698

16474624

http://www.w3.org/2001/XMLSchema#string